What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes? - PACE-CME

What can new glucoselowering SGLTinhibitors add to CV risk management in diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Careful implementation of PCSK9 inhibitors in clinical practice
Careful implementation of PCSK9 inhibitors in clinical practice
CSI 2016 ESC
Careful implementation of PCSK9 inhibitors in clinical practice
- Prof. dr. Terje Pedersen
Interim results of new device for treatment resistant hypertension
Interim results of new device for treatment resistant hypertension
CSI 2016 ESC
Interim results of new device for treatment resistant hypertension
- Dr. Wilko Spiering
To SPRINT or not to SPRINT to a lower blood pressure target?
To SPRINT or not to SPRINT to a lower blood pressure target?
CSI 2016 ESC
To SPRINT or not to SPRINT to a lower blood pressure target?
Understanding why patients do not take their medication and stimulating adherence
Understanding why patients do not take their medication and stimulating adherence
CSI 2016 ESC
Understanding why patients do not take their medication and stimulating adherence
- Prof. Robert Horne